Select Language
LILRB1
LILRB1 Overview
| English Name | Leukocyte immunoglobulin-like receptor B1 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 6 | Target Synonym | Leukocyte Immunoglobulin Like Receptor B1，LIR-1，MIR-7，ILT2，LIR1，Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 Soluble Isoform，PIR-B，Leukocyte immunoglobulin-like receptor 1，MIR7，PIRB，CD85j，Immunoglobulin-like transcript 2，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 1，Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1，Monocyte/Macrophage Immunoglobulin-Like Receptor 7，CD85 Antigen-Like Family Member J，Myeloid Inhibitory Receptor 7，Leucocyte Ig-Like Receptor B1，ILT-2，CD85j Antigen，Ig-Like Transcript 2 |
| Highest Development Stage | Phase 2 Clinical | ||
| English Name | Leukocyte immunoglobulin-like receptor B1 |
| Target Synonym | Leukocyte Immunoglobulin Like Receptor B1，LIR-1，MIR-7，ILT2，LIR1，Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 Soluble Isoform，PIR-B，Leukocyte immunoglobulin-like receptor 1，MIR7，PIRB，CD85j，Immunoglobulin-like transcript 2，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 1，Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1，Monocyte/Macrophage Immunoglobulin-Like Receptor 7，CD85 Antigen-Like Family Member J，Myeloid Inhibitory Receptor 7，Leucocyte Ig-Like Receptor B1，ILT-2，CD85j Antigen，Ig-Like Transcript 2 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 6 |
| Highest Development Stage | Phase 2 Clinical |
LILRB1 Product List
- Product Category
Protein (7)
- Product Status
Launched (7)
- Species
Human (6)Cynomolgus (1)
- Tag
Fc Tag (1)Fc Tag & Avi Tag (2)His Tag (3)His Tag & Avi Tag (1)
- Conjugate
Unconjugated (4)Biotin-labeled (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CDJ-H52H4 |  Human | HEK293 | Human LILRB1 / CD85j / ILT2 Protein, His Tag (MALS verified) |  |  |  |
HOT CDJ-H52H6 | Human | HEK293 | Human LILRB1 / CD85j / ILT2 (23-431) Protein, His Tag (MALS verified) |  | | |
HOT CDJ-H82E8 | Human | HEK293 | Biotinylated Human LILRB1 / CD85j / ILT2 Protein, His,Avitag™ (MALS verified) |  | | |
HOT CDJ-C52H3 |  Cynomolgus | HEK293 | Cynomolgus LILRB1 / CD85j / ILT2 Protein, His Tag |  | | |
CDJ-H5252 | Human | HEK293 | Human LILRB1 / CD85j / ILT2 Protein, Fc Tag (MALS verified) |  | |  |
CDJ-H82F7 | Human | HEK293 | Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™ |  | | |
CDJ-H82F9 | Human | HEK293 | Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™ (MALS verified) |  | |
Total: 7
- 1
LILRB1 Background
This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
LILRB1 Synonyms
CD85J,LILRB1,CD85,ILT2,LIR1,MIR7
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| NGM-707 | NGM-707 | Phase 2 Clinical | Merck & Co, NGM Biopharmaceuticals Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Melanoma; Mesothelioma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Zamristobart | BND-22; SAR-444881 | Phase 2 Clinical | Biond Biologics Ltd | Neoplasms; Solid tumours | Details |
| IOS-1002 | ios-H2 | Phase 1 Clinical | ImmunOs Therapeutics AG | Hematologic Neoplasms; Solid tumours | Details |
| AK-150 (Akeso) | AK150; AK-150 | Phase 1 Clinical | Solid tumours | Details | |
| LB-LR1109 | LB-LR1109; LR-19155; LR19155 | Phase 1 Clinical | Lg Chemical Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| AGEN-1571 | AGEN-1571 | Phase 1 Clinical | Agenus Inc | Neoplasms; Solid tumours | Details |
Product Reviews
M***n2025-04-24
0People LikeThis protein product from Acrobio Systems is high-quality and easy to use. The biotinylation via Avitag™ ensures consistent labeling, and the Fc tag provides good stability. It worked well in our binding assays, delivering reliable and reproducible results. Great option for researchers studying immune checkpoints or receptor-ligand interactions. Additionally, the protein was delivered quickly and arrived in excellent condition, with clear documentation and high purity confirmed by SDS-PAGE. It demonstrated strong and specific binding in flow cytometry and ELISA setups. The consistent performance across experiments made it a dependable tool in our studies. Highly recommended for immunology and cell biology applications where ligand-receptor interactions are key.- M***h2022-04-01 0People LikeThis sample was highly pure which was very helpful in selection campaigns to find specific molecules. We did our own QC on the sample to verify purity and it matched up perfectly with SDS-PAGE and SEC-MALS that is provided on the website. Shipping was quick to prevent delays in our project timelines. This sample was sent lyophilized and very easy to reconstitute for use.
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland